# 2 Supplemental Methods

# **3** Clinical Protocol

4 All participants were evaluated at the National Institutes of Health (NIH) between December 2021 and 5 May 2022 and enrolled in the clinical protocol: COVID-19-associated Lymphopenia Pathogenesis Study 6 in Blood (CALYPSO), NCT04401436. In brief, this protocol evaluates adults (18-years or older) with a 7 diagnosis of COVID-19 by a molecular or other commercial assay, or people who have recovered from 8 COVID-19. Participation includes clinical evaluation, standard of care clinical management as indicated, 9 laboratory studies, and research blood collection for storage of peripheral blood mononuclear cells 10 (PBMCs), serum, and plasma. Additionally, plasma samples were obtained from seven healthy volunteers 11 on a separate NIH IRB-approved protocol (NCT00001281). This was a convenience sample to provide a 12 healthy control comparison for the biomarker analysis and consisted of 5-women and 2-men with a 13 median age of 59-years (range: 45-66 years). All participants in both protocols provided written informed 14 consent prior to any study procedures in accordance with the Declaration of Helsinki.

15

# 16 Viral Sequencing

17 Initial detection and estimation of viral load by cycle threshold (Ct values) was performed using 18 Hologic® Panther Fusion® SARS-CoV-2 assay. Viral RNA sequencing was performed on SARS-CoV-2 19 positive nasal swab samples collected from patients with rebound symptoms as previously described (1). 20 Amplification of the viral genome was performed using a modified version of the ARTIC consortium 21 protocol for nCoV-2019 sequencing (https://artic.network/ncov-2019) and the methods available at 22 https://github.com/GhedinSGS/SARS-CoV-2 analysis. All libraries were prepped using the Nextera XT 23 library preparation kit (Nextera), scaled down to 0.25x of the manufacturer's instructions and libraries 24 were sequenced on the Illumina MiSeq using the 2x300 bp paired end protocol. Following sequencing,

samples were processed using the snakemake pipeline available at <u>https://glinub.com/GnedinsGS/SA</u>	ps://github.com/GhedinSGS/SA	peline available at http:	snakemake pr	d using the	imples were processed	25 sa
---	------------------------------	---------------------------	--------------	-------------	-----------------------	-------

26 <u>CoV-2 analysis</u>. The output from an in-house variant calling pipeline, timo, was used to identify

27 consensus changes. All analyses performed for this study are available at

28 <u>https://github.com/GhedinSGS/paxlovid-study</u>.

29

# 30 Viral Culture

31 Viral cultures were also performed on each sample by adding them to individual flasks containing Vero

32 E6 cells expressing the transmembrane serine protease, TMPRSS2 (VeroE6/TMPRSS2), obtained from

33 the Japanese Cell Culture collection (Osaka, Japan). Inoculations were performed as previously described

34 (2). The infected cells were incubated at 37° C with 5% CO2 and observed daily for cytopathic effects

35 (CPE). Upon observation of CPE the virus supernatant is harvested and sequenced. Finally, SARS-CoV-2

36 viral nucleocapsid protein levels were measured in serum using a single-molecule immune bead assay

37 (Quanterix, Billerica, MA) (3).

38

### **39** Serologic Assays

40 SARS-CoV-2 anti-spike (anti-S) and anti-receptor binding domain (anti-RBD) antibody responses were 41 analyzed by enzyme-linked immunosorbent assay (ELISA) using a previously validated technique (4). In 42 this study, a threshold of three standard deviations above the mean of the negative controls for both the 43 spike and RBD was determined to have a specificity of 100% for a positive result, and therefore was 44 considered the threshold for positivity. Levels of IgG, IgM, and IgA were determined for anti-S and anti-45 RBD and compared between the rebound cases and controls. Anti-nucleocapsid antibodies were evaluated 46 only for IgG and IgM. 47 The GenScript cPass assay, a surrogate viral neutralization test (sVNT) which has been shown to detect 48 neutralizing antibodies (5), was also performed to evaluate for the presence of anti-S neutralizing 49 antibodies against wild-type SARS-CoV-2 and the Omicron variant. This assay measures anti-S antibody-50 mediated inhibition of the interaction between the SARS-CoV-2 spike-RBD and the angiotensin-51 converting enzyme-2 (ACE2) receptor. The result is reported as percent binding inhibition of this 52 interaction. Diluted serum samples (1:10) were mixed with equal volume of HRP conjugated RBD 53 antigens and incubated for 30 minutes at 37° C. Then 100 ul of conjugates were transferred to the 54 microplate coated with ACE2-receptors and incubated for 15-minutes at 37° C. The microplate was 55 washed 4-times and incubated with TMB substrate in the dark for 15-minutes at room temperature for 56 color development. Absorbance was measured at 450 nm after addition of stop solution. The results were 57 calculated by the formula: Inhibition (%) =  $(1 - OD \text{ value of sample/OD value of negative control}) \times 100$ . 58 The results were interpreted as positive if  $\geq 30\%$  inhibition. For detection of neutralizing antibodies to the 59 BA.1 Omicron variant, the wild type S-RBD was replaced by the BA.1 S-RBD in the assay.

60

### 61 T-cell stimulation assays

62 Frozen PBMCs were thawed into pre-warmed R10 media (RPMI 1640, 10% FBS, 2 mM L-glutamine, 63 100 U/ml penicillin, and 100 µg/ml streptomycin) containing DNase I and rested for 1 hour (37°C/5% CO2). 1x10<sup>6</sup> to 1.5x10<sup>6</sup> PBMCs were aliquoted into 96-well V-bottom plates in 200 µL R10 and 64 65 stimulated with peptide pools (15mers overlapping by 11 amino acids) corresponding to the SARS-CoV-2 66 spike (wild-type), nucleocapsid and membrane proteins (2µg/mL final concentration; Genscript). Protein 67 transport inhibitors (ThermoFisher; cat. 00-4980-03) were included during the stimulation. Following 68 stimulation for 6 hours (37°C/5% CO2), PBMCs were washed with PBS, incubated with LIVE/DEAD 69 Fixable Blue Dead Cell Stain for 10 minutes and subsequently stained for surface markers (anti-CD3, 70 anti-CD4, anti-CD8, anti-TCRy\delta, anti-CCR7, anti-CD45RA and anti-PD-1) for 20 minutes. All 71 incubation steps during the staining were performed at room temperature. Cells were washed in PBS +

72 2% FBS, and subsequently fixed for 30 minutes (FoxP3/Transcription Factor Staining Buffer Set; ThermoFisher). Fixed PBMCs were washed in Permeabilization buffer and stained for intracellular 73 74 proteins (anti-CD69, anti-CD154, anti-IFNγ, anti-IL-2, anti-IL-4, anti-IL-13, anti-IL-21, anti-TNFα, anti-75 IL17 and anti-Ki67) for 30 minutes. Cells were again washed with Permeabilization buffer and fixed with 76 1% paraformaldehyde. Data were acquired on a modified BD FACSymphony and analyzed using FlowJo 77 software (version 10.7.1). Cytokine frequencies were background subtracted using a DMSO only 78 condition. Any CD4+ Th1-type response was determined using Boolean gating to include CD154+IFN $\gamma$ +, 79 CD154+IL-2+ or CD154+TNF $\alpha$ + responses. Two peptide pools were utilized to measure Spike-specific 80 responses, Spike pool A (peptides 1-160; residues 1-651) and Spike pool B (peptides 161-316; residues 81 641-1273) and responses from the two pools were summed to determine the response to full-length Spike.

82

#### 83 Antibodies for T cell stimulation assay

84 The following antibodies were purchased from BD Biosciences: CD3 BV786 (Clone SK7; cat. 563800), 85 CD4 BUV496 (Clone SK3; cat. 612936), CD8 BUV805(Clone SK1; cat. 612889), IFNy BB700 (Clone 86 B27; cat. 566394), TNFα BV750 (Clone MAb11; cat. 566359), IL-21 AlexaFluor647 (Clone 3A3-N2.1; 87 cat. 560493), IL-13 PE (Clone JES10-5A2; cat. 554571) Ki67 BV650 (Clone B56; cat. 563757) and CCR7 BUV395 (Clone 150503; custom conjugation). Antibodies from Biolegend included: IL-2 BV421 88 89 (Clone MQ1-17H12, cat. 500328), CD154 BV605 (Clone 24-31; cat. 310826), CD69 BV711 (Clone 90 FN50, cat. 310944), IL-4 PE (Clone MP4-25D2, cat. 500810), CD45RA BV570 (Clone HI100; cat. 91 304132) and PD-1 PE-Cy7 (Clone EH12.2H7; cat. 329918). Anti-TCRγδ APC-Vio770 (Clone REA591, 92 cat. 130-113-509) was from Miltenyi.

93

# 94 Soluble Biomarkers

95	Plasma samples were used to measure the following biomarkers according to the manufacturer's
96	instructions. Plasma levels of interleukin (IL)-6, IL-8, IL-10, IL-18, tumor necrosis factor-α (TNFα),
97	interferon- $\gamma$ (IFN $\gamma$ ), and chemokine (C-X-C motif) ligand 10 (CXCL10) were quantified by
98	electrochemiluminescence assays from Meso Scale Discovery platforms (Gaithersburg, MD, USA).
99	Plasma levels of CXCL-9, soluble CD25 (sCD25), IL-18 binding protein (BP), and sCD14 were
100	quantified using enzyme-linked immunoassay (ELISA) kits from R&D Systems (Minneapolis, MN,
101	USA).
102	
103	Statistical Analysis
104	All statistical analyses were conducted using GraphPad Prism (version 9) and R software (version 4.1.0).
105	
106	1. Nussenblatt V, Roder AE, Das S, de Wit E, Youn JH, Banakis S, et al. Yearlong COVID-19
107	Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. J Infect
108	Dis. 2022;225(7):1118-23.
109	2. Bennett RS, Postnikova EN, Liang J, Gross R, Mazur S, Dixit S, et al. Scalable, Micro-
110	Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in
111	Human Clinical Samples. Viruses. 2021;13(5).
112	3. Group A-TBS, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, et al.
113	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According
114	to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med.
115	2022;175(2):234-43.
116	4. Klumpp-Thomas C, Kalish H, Drew M, Hunsberger S, Snead K, Fay MP, et al. Standardization
117	of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood
118	sampling. Nat Commun. 2021;12(1):113.

119	5. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus	
120	neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat	
121	Biotechnol. 2020;38(9):1073-8.	
122		
123		
124		
125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		
138		

#### Supplemental Table 1: Laboratory Values

	Acute (N=6)	Rebound after NMV-r (N=6)	Late (N=2)
Days from initial symptom onset to sample collection, median [Min, Max]	3 [2-4]	16 [11-17]	11 [8-14]
Absolute neutrophil count, median [Min-Max] (cells/µL)	2950 [2300- 6950]	4190 [3110-7740]	4560 [4300- 4820]
Absolute lymphocyte count, median [Min-Max] (cells/µL)	1370 [760-2450]	1570 [1250-2650]	1720 [1580- 1850]
C-reactive protein, median [Min- Max] (mg/L)	12.2 [1.1-27.9]	4.45 [0.2-24.2]	0.95 [0.6-1.3]
Ferritin, median [Min-Max] (µg/L)	178 [26-551]	192 [30-251]	72.5 [36-109]
CD4 T cells, median [Min-Max] (cells/µL)	521 [273-952]	643 [528-793]	703 [618-788]
CD8 T cells, median [Min-Max] (cells/µL)	301 [113-474]	587 [349-693]	471 [306-636]
LDH, median [Min-Max] (units/L)	171 [100-229]	182 [138-190]	164 [123-205]
D-dimer, median [Min-Max] (µg/mL)	0.37 [0.27-2.22]	0.36 [0.27-0.50]	0.50 [0.33-0.66]

#### Supplemental Table 2: Individual Patient Clinical Courses and Laboratory Values During Rebound 150

	NMV-r Recipient Rebound Patients						NMV-r
	1	2	3	4	5	6	Nonrecipient Rebound
Initial symptoms	Upper respiratory + constitutional	Upper and lower respiratory	Upper respiratory	Upper respiratory	Upper respiratory + constitutional	Upper respiratory + constitutional	Upper respiratory + constitutional
Day of illness NMV-r started	3	2	1	3	1	4	NA
Day of illness symptoms returned	15 <sup>a</sup>	11ª	11 <sup>b</sup>	14	14	11ª	9
Day symptoms returned after completing NMV-r	8	5	6	7	9	3	NA
Days from initial symptom onset to visit	16	11	13	16	16	17	14
Rebound symptom severity	Milder <sup>c</sup>	Milder <sup>c</sup>	Worse <sup>d</sup>	Milder <sup>c</sup>	Similar <sup>e</sup>	Milder <sup>c</sup>	Milder <sup>c</sup>
Temperature during evaluation (°Celsius)	36.6	37.4	36.5	36.4	36.8	36.4	36.5
Initial heart rate during evaluation (beats/minute)	86	74	120	93	60	77	70
Oxygen saturation during evaluation (percent)	97	99	98	97 <sup>f</sup>	97	99	100
Absolute neutrophil count (cells/µL)	3110	4370	4600	4000	7740	3520	4300
Absolute lymphocyte count (cells/µL)	1740	1250	2650	1800	1400	1300	1850
C-reactive protein (mg/L)	0.2	4.7	24.2	4.1	6.2	4.2	0.6
Ferritin (μg/L)	251	30	226	151	228	157	109

CD4 T cells (cells/µL)	598	NA	793	719	643	528	618
CD8 T cells (cells/µL)	631	NA	693	587	349	458	636
LDH (units/L)	183	138	172	184	190	180	123
D-dimer (µg/mL)	0.27	0.36	0.40	0.36	0.50	0.36	0.66

<sup>a</sup> Repeat home rapid antigen turned negative, then positive again during rebound.

<sup>b</sup> Repeat home rapid antigen turned weakly positive, then became strongly positive again during rebound.

<sup>°</sup> Typical upper respiratory symptoms returned, no other symptoms.

<sup>d</sup> Upper respiratory symptoms returned and developed new lower respiratory symptoms (dyspnea on exertion).

<sup>e</sup> Upper respiratory symptoms as well as constitutional symptoms (fevers and myalgias) returned.

<sup>f</sup>Oxygen saturation was 94% after exertion and returned to normal range with rest.

157

158

159

	Patient 1 Acute	Patient 1 Rebound	Patient 2 Acute <sup>a</sup>	Patient 2 Rebound
Days from initial symptom onset to sample	3	16	4	11
Absolute neutrophil count (cells/µL)	2300	3110	2390	4370
Absolute lymphocyte count, median (cells/µL)	1370	1740	1370	1250
C-reactive protein (mg/L)	9.90	0.20	5.80	4.70
Ferritin (µg/L)	216	251	38.0	30.0
CD4 T cells (cells/µL)	487	598	583	NA
CD8 T cells (cells/µL)	474	631	259	NA
D-dimer (µg/mL)	0.27	0.27	0.37	0.36
LDH (units/L)	147	183	194	138

# 165 Supplemental Table 3: Patient 1 and 2 Acute and Rebound Timepoints

<sup>a</sup> Baseline evaluations were done after first 24 hours of NMV/r.



# 176 Supplemental Figure-1: Innate and adaptive biomarkers across study groups compared to healthy 177 controls. Lines represent medians and points represent individual results across the acute (red), rebound 178 (blue) and late presentation (black) COVID-19 clinical groups compared to healthy control population 179 (green). Healthy controls consisted of 5-women and 2-men with a median age of 59-years (range: 45-66 180 years). These samples were unmatched and included to provide a baseline range for these biomarkers in an otherwise healthy population. The two longitudinal COVID-19 rebound patients are identified by an 181 182 open diamond (Patient-1) and open triangle (Patient-2). The open square represents the COVID-19 183 rebound patient that did not receive NMV-r. Innate biomarkers (IL-6, IL-8, TNFa, CXCL-10, sCD14, and 184 IL-18BP) classically increased in acute COVID-19 are down trending at time of rebound. Adaptive 185 biomarkers representing T-cell activation (IFNy, CXCL-9, sCD25) were stable or increasing at rebound 186 consistent with a developing T-cell response. Abbreviations: IL – interleukin, sCD25 – soluble CD25, 187 IFNγ – interferon-γ, TNFα – tumor necrosis factor-α, CXCL-10 - chemokine (C-X-C motif) ligand 10, 188 IL-18BP - interleukin-18 binding protein.



191 Supplemental Figure-2: Summary of IgM and IgA antibody responses against SARS-CoV-2 192 proteins across the three groups. Lines represent medians and points represent individual results. 193 Longitudinal patient-2 is represented by an open triangle. ELISA data not available for longitudinal 194 patient-1 (diamond). The open square represents the COVID-19 rebound patient that did not receive 195 NMV-r. IgM and IgA antibody responses against spike protein and receptor binding domain (A-B, D-E). 196 IgM anti-nucleocapsid (N) antibody response (C). Surrogate virus neutralization test (sVNT) presented as 197 percent binding inhibition against Omicron SARS-CoV-2 spike protein negatively correlated with serum 198 nucleocapsid antigen (pg/mL) (R = -0.30 by Spearman's correlation with p = 0.028) (F). Abbreviations: 199 OD – optical density, RBD – receptor binding domain, N – nucleocapsid protein, sVNT – surrogate virus 200 neutralization test, Ab – antibody, Ag – antigen.